Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146920 · ClinicalTrials.gov registry record · NA
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
A NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT06146920: Active NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Massachusetts General Hospital.
NCT06146920 is a NA study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 39 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06146920, a NA study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have an increased 12-month disease free survival in comparison to historical controls?
Primary Outcome
Disease-free survival is defined as the time of determination of ctDNA negativity to the earlier of progression or death. This will be measured in days.
Conditions Studied
Interventions
- OTHER Evaluation of ctDNA using the F1T after 1 year of immunotherapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2028-11 |
| Phase | NA |
What the registry record for NCT06146920 still lists
NCT06146920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Evaluation of ctDNA using the F1T after 1 year of immunotherapy is the first listed.
NCT06146920 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06146920 about?
NCT06146920 is a clinical study titled "Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation". The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who ha...
What is the current status of trial NCT06146920?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 39 participants. The study started on 2024-01-10. Estimated completion is 2028-11.
What conditions does trial NCT06146920 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma.
What interventions are being tested in trial NCT06146920?
The interventions under investigation include: Evaluation of ctDNA using the F1T after 1 year of immunotherapy (OTHER).
Who is sponsoring clinical trial NCT06146920?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146920 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06146920's enrollment target sits among peer trials
39 369th of 454 higher than 83 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
RECRUITING · NA
-
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI